Notify me when Cowen Financial Products LLC files a new Schedule 13D/G report.
⭐ Subscribe ⭐| Sym | Company | Class | Ownership | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|---|
| XGN | Exagen Inc. | Common Stock, par value $0.001 per share | 5% | $3.64M | 891K | Cowen Financial Products LLC | Mar 31, 2025 | ||
| TARS | Tarsus Pharmaceuticals Inc. | Common Stock, $0.0001 par value per share | 4.9% | $88.6M | 1.91M | Cowen Financial Products LLC | Dec 31, 2024 | ||
| URGN | UroGen Pharma Ltd. | Ordinary Shares, par value NIS 0.01 per share | 0% | $0 | -$63.7M | 0 | -100% | Cowen Financial Products LLC | Sep 30, 2025 |
| STOK | Stoke Therapeutics Inc | Common Stock, $0.0001 par value per share | 0% | $0 | -$74.6M | 0 | -100% | Cowen Financial Products LLC | Sep 30, 2025 |
| BRZH | Breeze Holdings Acquisition Corp | Common Stock, $0.0001 par value per share | 0% | 0 | Cowen Financial Products LLC | Mar 31, 2025 |
| Sym | Target | Class | Ownership | Change | Current Shares | Change | Value | Reporting name | Form | Report Period | Date Filed |
|---|